BioSpace News Archive

Michigan Voters Disapprove of Legislation Requiring a Prescription for OTC Cold & Allergy Medicines

Applied DNA Sciences Inc. announced that LineaRx, Inc. will ship TK7 and ConTRT amplicons to Takis/Evvivax next week as part of the companies’ Joint Development Agreement (“JDA”) entered into in September 2018.

Exact Sciences Corp. announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast.

For the past ten years, Direct Relief has partnered with companies and non profit safety net healthcare providers for an alternative to the traditional patient assistance model.

Evofem Biosciences, Inc.,, a clinical stage biopharmaceutical company, reported financial results for the three- and twelve- month periods ended December 31, 2018.

ImmunoGen, Inc. announced that its Phase 3 FORWARD I trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in either the entire study population or in the pre-specified subset of patients with high FRα expression.

Nichi-Iko Pharmaceutical Co., Ltd. and Sagent Pharmaceuticals, Inc. announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals.

Risankizumab (under the trade name SKYRIZI) is an investigational, humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit(4)

LEO Pharma A/S announced that 13 data abstracts, including seven oral presentations across atopic dermatitis, chronic hand eczema, psoriasis and actinic keratosis will be presented during the 2019 American Academy of Dermatology Annual Meeting in Washington, D.C.

MaxCyte, the global cell-based medicines and life sciences company, announced that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement.